Zacks: Brokerages Expect Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.97 Per Share

Wall Street analysts expect that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will post ($0.97) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.77) and the lowest estimate coming in at ($1.17). Ritter Pharmaceuticals posted earnings per share of ($1.10) during the same quarter last year, which indicates a positive year-over-year growth rate of 11.8%. The company is expected to issue its next earnings results on Tuesday, November 13th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($2.97) per share for the current year, with EPS estimates ranging from ($3.30) to ($2.63). For the next fiscal year, analysts expect that the firm will post earnings of ($1.76) per share, with EPS estimates ranging from ($2.12) to ($1.40). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.15).

RTTR has been the subject of several research analyst reports. HC Wainwright set a $15.00 price target on Ritter Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 15th. ValuEngine upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research lowered Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th.

In related news, Director Matthew W. Foehr bought 19,751 shares of the firm’s stock in a transaction that occurred on Friday, August 17th. The stock was purchased at an average cost of $2.04 per share, for a total transaction of $40,292.04. Following the completion of the acquisition, the director now owns 54,751 shares in the company, valued at approximately $111,692.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 21.60% of the company’s stock.

Ritter Pharmaceuticals stock traded up $0.02 during mid-day trading on Wednesday, hitting $0.94. The company’s stock had a trading volume of 700 shares, compared to its average volume of 138,631. The firm has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.20 and a beta of 1.21. Ritter Pharmaceuticals has a 1 year low of $0.80 and a 1 year high of $4.00.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Recommended Story: Fiduciary

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply